登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《CELL，4月18日，Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-04-18

  • Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with

    mild/moderate COVID-19: an exploratory randomized controlled trial

    Yueping Li1,*

    , Zhiwei Xie1,*

    , Weiyin Lin1,*

    , Weiping Cai1,*

    , Chunyan Wen1

    , Yujuan

    Abstract (249 words)

    Background: Antiviral therapies against the novel coronavirus SARS-CoV-2,

    which has caused a global pandemic of respiratory illness called COVID-19,

    are still lacking.

    Methods: Our study (NCT04252885, named ELACOI), was an exploratory

    randomized (2:2:1) controlled trial assessing the efficacy and safety of

    lopinavir/ritonavir (LPV/r) or arbidol monotherapy for treating patients with

    mild/moderate COVID-19.

  • 原文来源：https://marlin-prod.literatumonline.com/pb-assets/products/coronavirus/MEDJ1.pdf
13浏览量
原文链接
相关报告

  • 《MedRxiv，3月23日，An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-24
    • An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI) Yueping Li, Zhiwei Xie, Weiyin Lin, Weiping Cai, Chunyan Wen, Yujuan Guan, Xiaoneng Mo, Jian Wang, Yaping Wang, Ping Peng, Xudan Chen, Wenxin Hong, Guangming Xiao, Jinxin Liu, Lieguang Zhang, Fengyu Hu, Feng Li, Feng Li, Fuchun Zhang, Xilong Deng, Linghua Li doi: https://doi.org/10.1101/2020.03.19.20038984 Abstract Background: The novel coronavirus pneumonia (COVID-19) outbreak has caused a global pandemic, however, effective antiviral therapeutics are still unavailable. Methods: Our study (NCT04252885), designated as ELACOI, was an exploratory randomized (2:2:1) and controlled one, exploring the efficacy and safety of lopinavir/ritonavir (LPV/r) or arbidol monotherapy treating mild/moderate COVID-19 patients. Results: This study successful enrolled 44 patients with mild/moderate COVID-19, with 21 randomly assigned to receive LPV/r, 16 to arbidol and 7 to no antiviral medication as control. Baseline characteristics of three groups were comparable. The median time of positive-to-negative conversion of SARS-CoV-2 nucleic acid was 8.5 (IQR 3, 13) days in the LPV/r group, 7 (IQR 3, 10.5) days in the arbidol group and 4 (IQR 3, 10.5) days in the control group (P=0.751). *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    53浏览量
    原文链接

  • 《NEJM，3月18日，A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-19
    • A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 List of authors. Bin Cao, M.D., Yeming Wang, M.D., Danning Wen, M.D., Wen Liu, M.S., Jingli Wang, M.D., Guohui Fan, M.S., Lianguo Ruan, M.D., Bin Song, M.D., Yanping Cai, M.D., Ming Wei, M.D., Xingwang Li, M.D., Jiaan Xia, M.D., et al. Abstract BACKGROUND No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. METHODS We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao2) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) of less than 300 mm Hg. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir–ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first.
    16浏览量
    原文链接